Latest News

The T1DAL ITN045AI clinical research study for recently diagnosed type 1 diabetes has completed enrollment at 19 clinical centers across the U.S. T1DAL is a randomized, placebo-controlled research study for participants between the ages of 12-35 and recently diagnosed with type 1 diabetes. The goal of this trial is to determine whether the drug alefacept (Amevive ®) can delay or permanently halt the destruction of beta cells in new-onset type 1 diabetes.

Results from the ITN020AI STAyCIS study, testing atorvastatin therapy in early multiple sclerosis, were just published in Neurology. The study, led by Scott Zamvil, MD (University of California, San Francisco), evaluated the safety and efficacy of atorvastatin (Lipitor®, Pfizer) in subjects with early signs that often lead to multiple sclerosis (MS), termed clinically isolated syndrome (CIS).  Previous preclinical studies demonstrated the ability of statins to reduce disease activity in MS models.

The ITN524ST-CTOT12 ARTIST  study on renal transplantation and the ITN signature of tolerance, recently met the target enrollment of 250 participants. This collaborative study between the Immune Tolerance Network (ITN) and the Clinical Trials in Organ Transplantation (CTOT) consortium, led by Drs. Kenneth Newell (Emory University), Laurence Turka (Harvard University), and Anil Chandraker (Brigham and Women’s Hospital), is an observational study for people who received a kidney transplant within the past 1 to 5 years.

The ITN is currently seeking short “Concept Proposals” for novel combination therapy clinical trials designed to induce immune tolerance in allergy and asthma.